A Covid testing company that once handled nearly a third of rapid testing in some states has agreed to pay $4.87 million to settle claims that it gouged patients during the pandemic, charging as much as $380 per test and tacking on hidden administrative fees while delivering results days late.
GS Labs, now permanently closed, faced a lawsuit brought by 18 states alleging the company inflated prices, misled insured customers about out-of-pocket costs, and failed to return results within its advertised three-day window. Residents of 17 states may now be eligible to claim a share of the payout, The U.S. Sun reported.
The numbers tell a grim story about what happened when pandemic fear met unchecked pricing. Nearly 30,000 patients paid far above market price for their tests and are now due a share of $1.8 million. Another roughly 70,000 customers who were hit with alleged administrative fee schemes may claim from a separate $1.7 million pool.
Investigators examined GS Labs' nationwide testing procedures between 2020 and 2022. What they found, the lawsuit claimed, was a company that took advantage of Americans at their most desperate, when a negative test result was the only ticket to a family visit, a flight, or a return to work.
GS Labs charged up to $380 for a single Covid test. For tests that checked for Covid alongside other illnesses, the price climbed as high as $1,000. Court documents stated that the company told insured patients they would face no extra costs, and then charged administrative fees as high as $49 per test.
At a time when many American households were already rethinking how they spent every dollar, those hidden charges added up fast.
The timing failures may have been just as damaging. GS Labs advertised results within three days. Hundreds of thousands of customers were allegedly left waiting far longer, sometimes a week or more. For anyone who needed a negative result to board a plane, attend a funeral, or show up for a job, a week-long delay wasn't an inconvenience. It was a broken promise with real consequences.
Minnesota Attorney General Keith Ellison, one of the investigators, did not mince words about the company's conduct.
"I have no patience for pandemic profiteers like GS Labs that deliberately overcharged for COVID-19 tests and deceived Minnesotans about the out-of-pocket costs they would have to pay."
Ellison also pointed to the human cost of delayed results:
"I'm sure many Minnesotans made plans to travel, to see family, or to attend events that depended on getting quick COVID-19 test results, and GS Labs' failure to produce quick test results caused significant problems in people's lives."
The company, for its part, did not go quietly. In a statement provided to First Alert 6, GS Labs said it was founded in direct response to the Covid-19 pandemic and ultimately tested more than 1.4 million Americans. The company claimed it identified approximately 200,000 positive cases.
GS Labs also said that at its peak, it handled 20 to 30 percent of the rapid testing market in states such as Minnesota and Washington. And it noted that the settlement expressly denies the allegations against the company.
That denial is worth weighing against the scope of the complaint. Eighteen state attorneys general do not typically band together over a minor billing dispute. The breadth of the lawsuit, spanning from Alabama to Washington, suggests investigators saw a pattern, not an isolated mistake.
The tension between corporate scale and consumer harm is a recurring theme in American commerce. Whether it's rural communities pushing back against powerful corporate interests or workers caught in the crosscurrents of corporate restructuring, the little guy often pays the price first and gets made whole last, if ever.
Residents of 17 states may be eligible for cash back: Alabama, Arizona, Colorado, Illinois, Indiana, Iowa, Kansas, Massachusetts, Minnesota, Missouri, New Jersey, North Dakota, Ohio, Oregon, Pennsylvania, South Dakota, and Washington.
The settlement splits into two main pools. The first, $1.8 million, covers the nearly 30,000 patients who paid above-market prices for tests. The second, $1.7 million, is earmarked for the roughly 70,000 customers affected by the alleged administrative fee scheme.
The exact claims deadline, full eligibility criteria, and whether the settlement has received final court approval were not detailed. Consumers in those states who used GS Labs between 2020 and 2022 should watch for further announcements.
Even divided among tens of thousands of claimants, the payouts will be modest. The math is simple: $1.8 million split among 30,000 people works out to roughly $60 each. That's a fraction of what a single overpriced test may have cost them. For the 70,000 in the admin-fee pool, the per-person figure is even smaller.
Settlements like this rarely make victims whole. They make headlines, cover legal fees, and deliver a check that barely covers a tank of gas. Meanwhile, the company that collected the money is already gone, permanently closed, beyond the reach of any further accountability.
GS Labs is hardly the only entity accused of profiting from the chaos of Covid. The pandemic created a gold rush for testing companies, PPE suppliers, and government contractors who operated in a market where demand was infinite, oversight was thin, and desperate people had no real choice but to pay whatever was asked.
The federal government poured trillions into pandemic response. Much of that money flowed through hastily assembled programs with minimal guardrails. When the dust settled, fraud and abuse were everywhere, from inflated PPE contracts to bogus loan applications. The GS Labs case fits neatly into that broader pattern of opportunism.
For the working Americans who stood in line at testing sites, often outdoors, often for hours, the promise was straightforward: get tested, get results, get back to your life. GS Labs allegedly broke that bargain at every step: inflated prices, hidden fees, and results that arrived long after they mattered.
Ellison framed the settlement as a measure of accountability:
"Today's settlement holds GS Labs accountable for overcharging consumers and misrepresenting their services."
Whether $4.87 million constitutes real accountability for a company that tested 1.4 million people and operated across dozens of states is a fair question. The settlement amount, while not trivial, represents a fraction of the revenue a nationwide testing operation would have generated during the peak of pandemic demand.
Several details remain unclear. The lawsuit was filed by 18 states, yet only 17 are listed as eligible for settlement claims. The specific court, case number, and statutes involved were not identified in available reporting. The exact date GS Labs shut its doors is also unknown.
For consumers in the eligible states, the practical question is whether the claims process will be simple enough to justify the effort. Class-action and multistate settlements often come with paperwork requirements that discourage all but the most persistent claimants. That benefits the settling party, fewer claims mean more money stays in the pot, or returns to the company.
In an economy where households are already watching corporate giants reshape the labor market while family budgets stay tight, even a modest refund matters. But the larger lesson is one Americans keep learning the hard way: when a crisis hits, the people who profit from it rarely pay a price that matches what they took.
A $4.87 million settlement sounds like a lot, until you divide it among a hundred thousand people and realize the company already closed its doors. The profiteers cashed out. The patients get a check that won't cover the test they overpaid for.